This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor:—
Many glowing reports of the early beneficial effects of the isonicotinic acid hydrazides ("rimifon," "nydrazid," and "marsilid") in patients with tuberculosis have appeared in newspapers and magazines as well as in the medical journals. Little has been mentioned, however, about the emergence of drug resistant tubercle bacilli in the sputum of patients treated with these drugs. Since one of the major drawbacks to the use of streptomycin alone in pulmonary tuberculosis proved to be the rapid emergence of streptomycin resistant strains of tubercle bacilli, and this regardless of the dosage, it is important to determine as soon as possible whether the same situation will arise during therapy with the isonicotinic acid hydrazides.Six patients began to receive isonicotinic acid hydrazide ("rimifon") or its isopropyl derivative ("marsilid") on Jan. 18, 1952. All had chronic cavitary pulmonary tuberculosis that had not responded satisfactorily to previous treatment, including streptomycin and
Steenken W, Meade GM, Wolinsky E, Coates EO. DRUG RESISTANT TUBERCLE BACILLI FROM PATIENTS TREATED WITH ISONICOTINIC ACID HYDRAZIDES. JAMA. 1952;149(2):187. doi:10.1001/jama.1952.02930190089027
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: